Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017654
Disease: Glomerular Filtration Rate
Glomerular Filtration Rate 		0.100 GeneticVariation phenotype GWASCAT 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function. 28452372 2017
CUI: C0201976
Disease: Creatinine measurement, serum (procedure)
Creatinine measurement, serum (procedure) 		0.100 GeneticVariation phenotype GWASCAT 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function. 28452372 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 Biomarker group BEFREE DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. 16980615 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 GeneticVariation disease BEFREE DACH1 inhibited ligand-dependent activity of AR mutations identified in patients with androgen-insensitive prostate cancer. 19351840 2009
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.010 GeneticVariation disease BEFREE DACH1 inhibited ligand-dependent activity of AR mutations identified in patients with androgen-insensitive prostate cancer. 19351840 2009
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 AlteredExpression disease BEFREE DACH1 is frequently methylated in HCC and DACH1 expression is regulated by promoter hypermethylation. 23787902 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE DACH1 inhibits breast cancer cellular growth in an NAD and p53-dependent manner through direct protein-protein association. 23798621 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE DACH1 inhibits breast cancer cellular growth in an NAD and p53-dependent manner through direct protein-protein association. 23798621 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE DACH1 methylation was associated with late tumor stage, poor differentiation, and lymph node metastasis. 24149323 2013
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.030 PosttranslationalModification disease BEFREE DACH1 methylation was associated with late tumor stage, poor differentiation, and lymph node metastasis. 24149323 2013
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.060 Biomarker group BEFREE DACH1 is increased in patients showing longer cancer specific survival and disease free interval and reduced metastasis formation (p<0.001). 24392136 2014
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE DACH1 is increased in patients showing longer cancer specific survival and disease free interval and reduced metastasis formation (p<0.001). 24392136 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.050 Biomarker phenotype BEFREE DACH1 is increased in patients showing longer cancer specific survival and disease free interval and reduced metastasis formation (p<0.001). 24392136 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE DACH1 methylation was associated with poor differentiation (P<0.05) and late tumor stage (P<0.05). 24743895 2014
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 PosttranslationalModification disease BEFREE DACH1 is frequently methylated in hepatic and colorectal cancer. 24912879 2014
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.030 PosttranslationalModification disease BEFREE DACH1 is frequently methylated in hepatic and colorectal cancer. 24912879 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.050 AlteredExpression phenotype BEFREE DACH1 expression inhibited epithelial-mesenchymal transition and metastasis by inhibiting transforming growth factor (TGF)-β signalling and suppressed GC cell proliferation through inducing G2/M phase arrest. 24912879 2014
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 AlteredExpression disease BEFREE DACH1 expression inhibited epithelial-mesenchymal transition and metastasis by inhibiting transforming growth factor (TGF)-β signalling and suppressed GC cell proliferation through inducing G2/M phase arrest. 24912879 2014
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.010 AlteredExpression disease BEFREE DACH1 expression inhibited epithelial-mesenchymal transition and metastasis by inhibiting transforming growth factor (TGF)-β signalling and suppressed GC cell proliferation through inducing G2/M phase arrest. 24912879 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.020 Biomarker phenotype BEFREE DACH1, a gene associated with tumor progression, was further analyzed. 25776071 2015
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 Biomarker disease BEFREE DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. 25788272 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE DACH1 performs an important role in the development of a number of neoplasms, and has the ability to regulate the Wnt/β-catenin signaling pathway as a novel predictive and diagnostic biomarker. 28927149 2017
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 Biomarker disease BEFREE DACH1 inhibits lung adenocarcinoma invasion and tumor growth but has a lower expression in NSCLC. 29590536 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE DACH1 inhibits lung adenocarcinoma invasion and tumor growth but has a lower expression in NSCLC. 29590536 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE DACH1 may act as a tumor suppressor gene and could be a potential target for therapeutic intervention of LSCC. 30261897 2018